A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis.
Adult
Aged
Drug Combinations
Ferric Compounds
/ therapeutic use
Humans
Hyperphosphatemia
/ drug therapy
Hypoalbuminemia
/ drug therapy
Middle Aged
Nutritional Status
Peritoneal Dialysis
/ adverse effects
Phosphates
Phosphorus
Pilot Projects
Prospective Studies
Serum Albumin
Sucrose
/ therapeutic use
Albumin
Appetite
Binders
Dialysis
Peritoneal
Phosphorus
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
09 07 2022
09 07 2022
Historique:
received:
27
03
2022
accepted:
30
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
Hyperphosphatemia is common in patients on peritoneal dialysis (PD). Restricting dietary phosphorus often leads to a decrease in protein intake, which may result in hypoalbuminemia. The high pill burden of phosphate binders may also contribute to compromised appetite and dietary intake. Hypoalbuminemia is associated with an increased risk of morbidity and mortality in PD patients. The goal of this study was to determine if sucroferric oxyhydroxide improves albumin and self-reported measures of appetite in PD patients. We performed a prospective, open-label, 6-month, pilot study of 17 adult PD patients from the Denver Metro Area. Patients had to use automated peritoneal dialysis for ≥ 3 months, have a serum albumin ≤ 3.8 g/dL, and have serum phosphate ≥ 5.5 mg/dL or ≤ 5.5 mg/dL on a binder other than SO. SO was titrated to a goal serum phosphate of < 5.5 mg/dL. The primary outcome was change in serum phosphate, albumin, and phosphorus-attuned albumin (defined as albumin divided by phosphorus) over 6 months. The mean (SD) age and dialysis vintage was 55 ± 13 years and 3.8 ± 2.7 years, respectively. Participants' serum phosphate significantly decreased with fewer phosphate binder pills/day after switching to SO. There was no change in serum albumin, appetite, or dietary intake. However, participants had significant improvements in phosphorus-attuned albumin. The transition to SO improved phosphorus control, phosphorus-attuned albumin, and pill burden. There were no significant changes in self-reported appetite or dietary intake during the study. These findings suggest that PD patients maintained nutritional status with SO therapy. First registered at ClinicalTrials.gov ( NCT04046263 ) on 06/08/2019.
Sections du résumé
BACKGROUND
Hyperphosphatemia is common in patients on peritoneal dialysis (PD). Restricting dietary phosphorus often leads to a decrease in protein intake, which may result in hypoalbuminemia. The high pill burden of phosphate binders may also contribute to compromised appetite and dietary intake. Hypoalbuminemia is associated with an increased risk of morbidity and mortality in PD patients. The goal of this study was to determine if sucroferric oxyhydroxide improves albumin and self-reported measures of appetite in PD patients.
METHODS
We performed a prospective, open-label, 6-month, pilot study of 17 adult PD patients from the Denver Metro Area. Patients had to use automated peritoneal dialysis for ≥ 3 months, have a serum albumin ≤ 3.8 g/dL, and have serum phosphate ≥ 5.5 mg/dL or ≤ 5.5 mg/dL on a binder other than SO. SO was titrated to a goal serum phosphate of < 5.5 mg/dL. The primary outcome was change in serum phosphate, albumin, and phosphorus-attuned albumin (defined as albumin divided by phosphorus) over 6 months.
RESULTS
The mean (SD) age and dialysis vintage was 55 ± 13 years and 3.8 ± 2.7 years, respectively. Participants' serum phosphate significantly decreased with fewer phosphate binder pills/day after switching to SO. There was no change in serum albumin, appetite, or dietary intake. However, participants had significant improvements in phosphorus-attuned albumin.
CONCLUSION
The transition to SO improved phosphorus control, phosphorus-attuned albumin, and pill burden. There were no significant changes in self-reported appetite or dietary intake during the study. These findings suggest that PD patients maintained nutritional status with SO therapy.
TRIAL REGISTRATION
First registered at ClinicalTrials.gov ( NCT04046263 ) on 06/08/2019.
Identifiants
pubmed: 35810296
doi: 10.1186/s12882-022-02878-5
pii: 10.1186/s12882-022-02878-5
pmc: PMC9271241
doi:
Substances chimiques
Drug Combinations
0
Ferric Compounds
0
Phosphates
0
Serum Albumin
0
sucroferric oxyhydroxide
0
Phosphorus
27YLU75U4W
Sucrose
57-50-1
Banques de données
ClinicalTrials.gov
['NCT04046263']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Informations de copyright
© 2022. The Author(s).
Références
J Ren Nutr. 2011 Mar;21(2):176-83
pubmed: 21193323
Clin J Am Soc Nephrol. 2012 Jul;7(7):1155-62
pubmed: 22554719
BMC Nephrol. 2019 Oct 29;20(1):396
pubmed: 31664928
Curr Pharm Des. 2014;20(37):5829-33
pubmed: 24533939
J Nephrol. 2022 Apr;35(3):875-888
pubmed: 35138627
Perit Dial Int. 1996;16 Suppl 1:S181-4
pubmed: 8728189
J Ren Nutr. 2019 Sep;29(5):428-437
pubmed: 30679076
Am J Kidney Dis. 1995 Aug;26(2):353-61
pubmed: 7645541
J Am Soc Nephrol. 2005 Feb;16(2):520-8
pubmed: 15615819
Kidney Int Suppl. 2008 Apr;(108):S152-8
pubmed: 18379539
Nephrol Dial Transplant. 2003 Oct;18(10):2134-40
pubmed: 13679492
Adv Perit Dial. 2013;29:55-60
pubmed: 24344493
Nephrol Dial Transplant. 2015 Jun;30(6):1037-46
pubmed: 25691681
Am J Kidney Dis. 2008 Sep;52(3):519-30
pubmed: 18514987
Clin J Am Soc Nephrol. 2009 Oct;4(10):1646-54
pubmed: 19808245
Kidney Int Rep. 2021 Jan 07;6(2):304-312
pubmed: 33615055
Am J Nephrol. 2018;47(3):153-161
pubmed: 29514139
J Ren Nutr. 2009 Mar;19(2):127-35
pubmed: 19218039
Am J Kidney Dis. 1998 Dec;32(6 Suppl 4):S118-25
pubmed: 9892378
J Ren Nutr. 2011 Jan;21(1):12-5
pubmed: 21195910
Perit Dial Int. 2003 Nov-Dec;23(6):550-6
pubmed: 14703195